DUBLIN--(http://www.researchandmarkets.com/research/f7stp3/randd_trends_alle) has announced the addition of the "R&D Trends: Allergic Rhinitis - Immunotherapy Dominates the Pipeline" report to their offering.)--Research and Markets (
“R&D Trends: Allergic Rhinitis - Immunotherapy Dominates the Pipeline”
Overview of the allergic rhinitis pipeline, from preclinical to preregistration, with analysis by phase and formulation, as well as discussion of clinical trial design and trends. The future of treatment is assessed based on progress in development.
The 2012 pipeline shows continued strong interest in immunotherapy, which makes up 43% of products in development. Advancements in clinical trials and key partnerships are increasing exposure of this class. In this largely stable market, areas of innovation exist with nasal antihistamine/corticosteroid combinations showing progress, while a number of novel targeted therapies raise skepticism.
- Datamonitor has identified 65 products in development for allergic rhinitis. The late-stage pipeline is heavily skewed towards immunotherapy, which makes up all 15 Phase III products. Immunotherapy shows the greatest innovation, with considerable change to clinical trials, and an increased focus on sublingual tablet franchises.
- Discussions with key opinion leaders reveal a largely stable market for symptomatic treatment; however, areas of innovation exist, such as the development of combination products. Analysis of comparator therapies highlights areas of unmet need.
- A number of novel targeted therapies are moving through the pipeline, including five CRTH2 antagonists. Key opinion leaders and recent discontinuations have cast skepticism over their clinical viability, with efficacy expected to fall short of established treatment classes. However, they may find a place in the treatment of select patient groups.
Key Topics Covered:
CLINICAL PIPELINE OVERVIEW
- Allergen immunotherapy dominates late-stage pipeline
- Analysis by formulation demonstrates innovation in the pipeline
- Late-stage discontinued development compounds
TARGET PRODUCT PROFILE
- Telfast/Allegra (fexofenadine; Sanofi)
- Nasonex (mometasone; Merck & Co.)
- Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN ALLERGIC RHINITIS
- Trends in clinical trial endpoints
- Allergy challenges tackle seasonal variations
- Study populations
- Comparator drugs
- Drug development guidelines in allergen immunotherapy
- Typical allergic rhinitis clinical trials
- Future developments in clinical trial design
INNOVATIVE EARLY-STAGE APPROACHES
- Sublingual immunotherapy franchises
- Histamine H4 receptor antagonist
- Novel targeted therapies
THE FUTURE OF TREATMENT IN ALLERGIC RHINITIS
- Dry aerosol steroid sprays and combination antihistamine/corticosteroid therapy
- Sublingual shift in immunotherapy
For more information visit http://www.researchandmarkets.com/research/f7stp3/randd_trends_alle